Pexelizumab Reduces Death and Myocardial Infarction in Higher Risk Cardiac Surgical Patients

The C5 complement inhibitor, pexelizumab, reduced morbidity and mortality among high-risk patients undergoing coronary artery bypass grafting with cardiopulmonary bypass.